Recombinant human interleukin-7

Phase 2Protein / enzyme

NNational Institute of Allergy and Infectious Diseases (NIAID)

Recombinant human interleukin-7 is one of 74 small molecule programs targeting Lung Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung DiseaseActive, not recruiting

LymphopeniaActive, not recruiting

AsthmaActive, not recruiting

Lung DiseasePhase 2

Active, not recruiting

LymphopeniaPhase 1/Phase 2

Active, not recruiting

AsthmaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Veramyst

GSK

Preclinical

46 2

Xolair

Roche

Preclinical

25 3

Singulair

AstraZeneca

Preclinical

17 4

Nucala

GGlaxo Dba Glaxosmithkline

Preclinical

35 5

Asmanex

Novartis

Preclinical

5 6

Celexa

AbbVie

Preclinical

1 7

Recombinant human interleukin-7

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 2

1 8

Aciphex

Akero Therapeutics

Preclinical

2 9

Aclidinium Bromide

Ozone

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Lymphopenia

NCT05600920

Clinical

Trials by Indication[1]

4 more indications

Adult1 trial

UMD rPA Regimen Trial in Adults

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00133484·270 enrolled

Single Dose1 trial

Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT02433652·24 enrolled

Lung Disease1 trial

Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease

Terminated·RRevimmune·Phase 2·NCT04154826·8 enrolled

Interleukin1 trial

Safety of Interleukin-7 in HIV Infected People Currently Taking Anti-HIV Drugs

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00099671·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Recombinant human interleukin-7. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Recombinant human interleukin-7 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Recombinant human interleukin-7. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 2[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

Recombinant human interleukin-7

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Asthma1 trial

Lymphopenia1 trial

Transgender Persons1 trial

Immunogenicity1 trial

Adjuvant1 trial

Adult1 trial

Single Dose1 trial

Lung Disease1 trial

Interleukin1 trial

References

Drug Info

Quick Facts

Related News